Halozyme Therapeutics (HALO) return on invested capital (ROIC)

Return on invested capital · fiscal 2025
26.6%

Halozyme Therapeutics (HALO) earned a return on invested capital of 26.6% in fiscal 2025 (the year ended December 31, 2025). That is 7.9 percentage points lower than the 34.5% of fiscal 2024. Figures as of 18 Nov 2026, 02:00 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on invested capital, fiscal 2025
26.6%
Change on fiscal 2024
−7.9 pts
Highest on record
34.5%fiscal 2024
Lowest on record
16.5%fiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Halozyme Therapeutics return on invested capital (ROIC), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 34.5% in fiscal 2024 and the lowest 16.5% in fiscal 2022. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 21.9%.

History · 4 fiscal years

Return on invested capital by fiscal year

Halozyme Therapeutics return on invested capital (ROIC), year by year

Halozyme Therapeutics (HALO) return on invested capital (ROIC) by fiscal year
Fiscal yearReturn on invested capitalChangeYear ended
202526.6% 7.9 pts down
202434.5% 12.6 pts up
202321.9% 5.3 pts up
202216.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

How to read it

It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.

Return on invested capital at health care companies of similar size

Return on invested capital of Halozyme Therapeutics and comparable companies
CompanyReturn on invested capitalFiscal year
Fresenius Medical Care FMS6.5%2025
Kymera Therapeutics KYMR-33.6%2025
DaVita DVA13.7%2025
Halozyme Therapeutics HALO26.6%2025
Universal Health Services UHS12.4%2025
Repligen RGEN1.6%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics return on invested capital (ROIC): questions and answers

What is Halozyme Therapeutics's return on invested capital?

Halozyme Therapeutics (HALO) earned a return on invested capital of 26.6% in fiscal 2025 (the year ended December 31, 2025). That is 7.9 percentage points lower than the 34.5% of fiscal 2024.

Is Halozyme Therapeutics's return on invested capital high or low compared with its own history?

The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 21.9%.

What are the highest and lowest return on invested capital figures on record for Halozyme Therapeutics?

Across the 4 fiscal years on record (2022–2025), the highest was 34.5% in fiscal 2024 and the lowest 16.5% in fiscal 2022.

How is Halozyme Therapeutics's return on invested capital calculated?

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) return on invested capital (ROIC)”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/roic

Underlying data: the company's filings with the SEC and Yahoo Finance.